Prof. Antonio Costanzo is the Dermatology Unit Director in Humanitas Research Hospital. He graduated with his MD degree in Medicine and Surgery from the University of Rome, La Sapienza in 1994. He then went on to complete post-graduate study and received a speciality degree in Internal Medicine in 1999 and a Dermatology speciality degree in 2006.
Medical areas of interest:
Previous experience:
Research areas of interest:
His clinical research is focused on the characterization of the activity of biologics in psoriasis and psoriatic arthritis. This research is strictly linked to basic research activity on the pathogenesis of psoriasis and on the use of pharmacogenetic approach to predict the efficacy and safety of biologics in psoriasis.
In the past, Professor Costanzo has collaborated to the characterization of basic mechanisms of TNF inflammatory signalling in epithelial cells and NFkappaB regulation by different stimuli. More recently his research group has collaborated to the discovery of IL-21 as critical mediator of keratinocyte proliferation in psoriasis. Professor Costanzo has authored or co-authored more than 120 publications in internationally peer-reviewed journals.
Teaching experience: Full Professor of Dermatology at Humanitas University
Publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=Costanzo+A
Read more
Prof. Antonio Costanzo is the Dermatology Unit Director in Humanitas Research Hospital. He graduated with his MD degree in Medicine and Surgery from the University of Rome, La Sapienza in 1994. He then went on to complete post-graduate study and received a speciality degree in Internal Medicine in 1999 and a Dermatology speciality degree in 2006.
Medical areas of interest:
Previous experience:
Research areas of interest:
His clinical research is focused on the characterization of the activity of biologics in psoriasis and psoriatic arthritis. This research is strictly linked to basic research activity on the pathogenesis of psoriasis and on the use of pharmacogenetic approach to predict the efficacy and safety of biologics in psoriasis.
In the past, Professor Costanzo has collaborated to the characterization of basic mechanisms of TNF inflammatory signalling in epithelial cells and NFkappaB regulation by different stimuli. More recently his research group has collaborated to the discovery of IL-21 as critical mediator of keratinocyte proliferation in psoriasis. Professor Costanzo has authored or co-authored more than 120 publications in internationally peer-reviewed journals.
Teaching experience: Full Professor of Dermatology at Humanitas University
Publications: https://www.ncbi.nlm.nih.gov/pubmed/?term=Costanzo+A
Professor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.
He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.
In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.
Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.
Current Positions:
In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).
Publications: santoro%a - Search Results - PubMed (nih.gov)
Read moreProfessor Santoro is heavily involved in research, with interest in many topics, such as the development of new cancer drugs and new biological therapies, interests for solid and haematological tumours, and not only he treats cancer survivors but also patients with comorbidities.
He has worked in Humanitas Research Hospital for 22 years. Professor Santoro’s post-graduate research was carried out at the Unité de Development Therapeutique (Institut de Cancerologie et d’Immunogenetique, Villejuif of Paris) from 1974 to 1975, and in the Division of Medical Oncology of the National Cancer Institute of Milan from 1976 to 1977.
In 1977, he specialized in Clinical and Laboratory Haematology at University of Rome. In 1979, he completed his fellowship post-graduate work in the Memorial Sloan Kettering Cancer Center of New York and later, at Stanford University. In 1980, he specialized in oncology at the University of Genoa.
Current Teaching Activity: Professor Santoro worked as Contract Professor at the Specialization School in Clinical Pathology ad Pavia University from 1992 to 1997. Also, from 1993 to 2002 he has been President of the Rare Tumour Group. Now he is full professor at Humanitas University.
Current Positions:
In addition, Professor Santoro’s unique expertise was recognized through numerous awards, such as the Managing Doctor of the Year award (2013), the City of Siena S. Caterina d’Oro Award (2013, Serra Association Award for scientific research) and social and healthcare commitment (Salerno, 2009).
Publications: santoro%a - Search Results - PubMed (nih.gov)